CTS-Clinical and Translational Science

Article	Citations
Gene polymorphism and prediction of toxicity to platinum‐based chemotherapy in patients with gynecologic cancer	262
Issue Information	123
Intradermal substance P as a challenge agent in healthy individuals	102
Issue Information	99
	79
Bridging Implementation Gaps in Digital Health: A Translational Research Imperative for Equitable Healthcare Innovation	76
ST2 and CSF‐1 as potential druggable targets of inflammatory bowel diseases: Results from two‐sample Mendelian randomization study	70
A Patient Centric Model for Vaso‐Occlusive Crises in Sickle Cell Disease—Outcomes of a Consensus Exercise Conducted Across Patients and Experts	63
The impact of skin color and tone on histamine iontophoresis and Doppler flowmetry measurements as a pharmacodynamic biomarker	58
CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin	53
Nontraditional Factors Influencing Cardiovascular Disease Risk: Correlation Among Framingham Risk Score, Body Composition Index, and Sleep‐Breathing Monitoring Index	51
Japanese Phase 1 Study for Global Development of Anti‐TL1A Antibody PF‐06480605: A Randomized, Placebo‐Controlled, Single‐Ascending Dose Study	49
A comprehensive Thai pharmacogenomics database (TPGxD‐1): Phenotype prediction and variants identification in 942 whole‐genome sequencing data	48
Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community	42
Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection	42
Patient, industry, and regulatory perspective on antibody‐drug conjugates dose optimization	41
Using partition analysis as a facile method to derive net clearances	39
Developing a clinical research infrastructure embedded in an academic medicine center that equitably supports future clinician scientists	39
From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry	36
Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications	35
Generalizability in real‐world trials	35
The Effect of Diabetes Medication on the Scores of the GNRI and CONUT Nutritional Indices: Cross‐S	34
Evidence of depot‐specific regulation of all‐trans‐retinoic acid biosynthesis in human adipose tissue	33
First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome	30
Risk factors for the development of sepsis in patients with cirrhosis in intensive care units	30

Expanding regulatory science: Regulatory complementarity and reliance	29
Pharmacogenomic landscape of Indian population using whole genomes	29
First, Do No Harm: Addressing AI's Challenges With Out‐of‐Distribution Data in Medicine	29
Pharmacokinetics and Toxicity of Dimethylacetamide and Its Metabolite in Pediatric Patients Treated With High Dose Intravenous Busulphan	26
Lexicon for blood‐based early detection and screening: BLOODPAC consensus document	26
Real‐world evidence to support regulatory submissions: A landscape review and assessment of use cases	25
Gossypol improves myocardial dysfunction caused by sepsis by regulating histone acetylation	25
Efficacy and safety of tofacitinib in rheumatoid arthritis: Nine years of real‐world data	25
Recommended Clinical Context and Patient Context Data Elements for Liquid Biopsy Data Submitted to Data Repositories and Data Commons	25
Risk Factors Analysis of Cutaneous Adverse Drug Reactions Caused by Targeted Therapy and Immunotherapy Drugs for Oncology and Establishment of a Prediction Model	25
Strengthening the Food and Drug Administration Office of Clinical Pharmacology's Labeling Authority	24
Concentration–Response Analysis of the Combination of Pyronaridine and Piperaquine on Corrected QT Interval From a Randomized, Double‐Blind, Placebo‐Controlled Study in Healthy Adults of Af	24
Utilization of Machine Learning Approaches for Drug Clearance Prediction and Population Pharmacokinetic Covariate Analysis	24
Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma	24
Feasibility study for a fully decentralized clinical trial in participants with functional constipation symptoms	23
Pharmacokinetics and Safety of Pelacarsen, a GalNAc 3 ‐Conjugated Antise	23
Radiolabelled Cyclodextrins for the Positron Emission Tomography Imaging of Breast Cancer: Preclinical Perspectives	23
Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3‐internal‐tandem‐duplication‐positive acute myeloid leukemia	22
Surrogate Endpoints in Pivotal Clinical Trials for Drug Approval in Japan Compared to the United States	22
Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants	22
Exploring the discrepancies between clinical trials and real‐world data: A small‐cell lung cancer study	22
Prevalence of actionable pharmacogenetic variants and high‐risk drug prescriptions: A Swiss hospital‐based cohort study	22
Human radiolabeled mass balance studies supporting the FDA approval of new drugs	21
Emapalumab in Patients With Macrophage Activation Syndrome Associated With Still's Disease: A Population Pharmacokinetic/Pharmacodynamic Analysis	21
Comprehensive analysis of clinical and biological features in Parkinson's disease associated with the LRRK2 G2019S mutation: Data from the PPMI study	21
First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor	20
Parkinson's disease: Still waiting for a cure	20
Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry – Informing optimal antiplatelet strategies	20
Use cases of registry‐based randomized controlled trials—A review of the registries' contributions and constraints	20
Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants	20
Phase 1 Study Evaluating the Pharmacokinetics, Dose Proportionality, Bioavailability, and Tolerability of Subcutaneous Levothyroxine Sodium (XP‐8121)	20
Issue Information	19
Effect of Whole‐Brain Radiotherapy Dose on the Occurrence of Otitis Media and Mastoiditis in Patients With Lung Cancer With Brain Metastasis	19
Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors	19
Effect of Selective Serotonin Reuptake Inhibitors on Coagulation: Fact or Fiction?	19
Assessment of QT Interval Prolongation Using Concentration– QT Modeling for Iptacopan, an Oral Com	18
Pediatric CYP2D6 metabolizer status and post‐tonsillectomy nausea and vomiting after ondansetron	18
Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC‐0214 in healthy volunteers	18
Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma Using Miriplatin Without the Need for Hydration	18
Issue Information	17
Hesitant adopters: An examination of hesitancy among adults in Arkansas who have taken the COVID‐19 vaccine	17
The Role of Candidate Polymorphisms in Drug Transporter Genes on High‐Dose Methotrexate in the Consolidation Phase of the AIEOP‐BFM ALL 2009 Protocol	17
Real‐world evidence in the cloud: Tutorial on developing an end‐to‐end data and analytics pipeline using Amazon Web Services resources	17
Comparing machine learning and deep learning models to predict cognition progression in Parkinson's disease	17
Colonic Tissue Expression of MAdCAM ‐1 Is Not Predictive of Vedolizumab Responsiveness in Inflammatory Bowel Disease	17
Real‐world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community‐based cancer center	17
Physiologically Based Pharmacokinetic Modeling of Valemetostat to Inform Dose Recommendations When Coadministered With CYP3A /P‐gp Modulators	17
Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact	17
Associations of HLA genetic variants with carbamazepine‐induced cutaneous adverse drug reactions: An updated meta‐analysis	17
Cardiovascular risk of urate‐lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan	17

Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science	17
Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study	17
A Tutorial and Use Case Example of the eXtreme Gradient Boosting (XGBoost) Artificial Intelligence Algorithm for Drug Development Applications	16
Lidocaine as an anti‐arrhythmic drug: Are there any indications left?	16
	16
	16
Academia and industry agreement on a feasibility tool for first‐time‐in‐human clinical trial units	16
Issue Information	16
Issue Information	16
Model‐informed precision dosing of teicoplanin for the rapid achievement of the target area under the concentration‐time curve: A simulation study	16
Mass Balance and Metabolism of 14 C ‐Atogepant in Healthy Male Participa	15
Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma	15
A Survey Study of Roadblocks in Translational Science	15
Association between statin use and dry eye disease in patients with hyperlipidemia: A population‐based retrospective cohort study	15
The Dorsal Forearm as a Novel Target for Intramuscular Injections: Clinical Pharmacokinetic Results With Naloxone	15
Issue Information	15
Prediction of molecular phenotypes for novel SCN1A variants from a Turkish genetic epilepsy syndromes cohort and report of two new patients with recessive Dravet syndrome	15
Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach	15
Integrating real‐world data and machine learning: A framework to assess covariate importance in real‐world use of alternative intravenous dosing regimens for atezolizumab	15
A Multicenter Randomized Controlled Study on Pharmacokinetic‐Guided Vancomycin Use in Children With Severe Infections	15
Issue Information	15
Issue Information	14
Penetration of linezolid and tedizolid in cerebrospinal fluid of mouse and impact of blood–brain barrier disruption	14
Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase‐4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas	14
Machine learning framework to predict pharmacokinetic profile of small molecule drugs based on chemical structure	14
Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta‐analysis	14
Issue Information	14
A First‐In‐Human Phase 1 Study to Evaluate the Safety and Tolerability of LEM‐S401, a Novel siRNA‐DegradaBALL Drug Targeting CTGF in Healthy Adul	14
Insights From a User Experience‐Focused Virtual Study on the Feasibility and Challenges of Decentralized Clinical Trials	14
PBPK‐led assessment of antimalarial drugs as candidates for Covid‐19: Simulating concentrations at the site of action to inform repurposing strategies	14
Engaging student opinions on vaccine development innovation: Experiences from a “Shark Tank” project	14
Predicted expression of genes involved in the thiopurine metabolic pathway and azathioprine discontinuation due to myelotoxicity	14
Free heme and hemopexin in acute kidney injury after cardiopulmonary bypass and transient renal ischemia	14
The “One‐Step” approach for QT analysis increases the sensitivity of nonclinical QTc analysis	14
Pharmacokinetic evaluation of radiolabeled intraocular anti‐CLEC14a antibody in preclinical animal species and application in humans	13
Characterization of Drug–Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS‐CoV‐2, in Healthy Participants	13
High intrapatient variability of tacrolimus exposure associated with poorer outcomes in liver transplantation	13
Association between aortic calcification and cytokine levels in patients with peripheral artery disease	13
A Patient‐Derived 3D Cyst Model of Polycystic Kidney Disease That Mimics Disease Development and Responds to Repurposing Candidates	13
Tutorial Drug–Drug Interactions	13
CYP2C8*3 and *4 define CYP2C8 phenotype: An approach with the substrate cinitapride	13
Artificial intelligence in rare disease diagnosis and treatment	13
Response to “DPYD genotyping panels: Impact of population diversity”	13
Physiologically based absorption modeling to predict the bioequivalence of two apixaban formulations	13
Dupilumab: Mechanism of action, clinical, and translational science	13
Issue Information	13
What motivates people with type 2 diabetes mellitus to participate in clinical trials from home?	13
	13
Proposing a framework to quantify the potential impact of pharmacokinetic drug–drug interactions caused by a new drug candidate by using real world data about the target patient population	13
Ascites affects the benefit of carvedilol on patients with liver cirrhosis and esophageal and gastric varices	13
Prediction of Cisplatin‐Induced Acute Kidney Injury Using an Interpretable Machine Learning Model and Electronic Medical Record Information	12
Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants	12
Anticoagulant therapy in COVID‐19: A narrative review	12
Preclinical assessment of drug–drug interaction of fb‐PMT, a novel anti‐cancer thyrointegrin αvβ3 antagonist	12
Safety, pharmacokinetics, and pharmacodynamics of ART‐648, a PDE4 inhibitor in healthy subjects: A randomized, placebo‐controlled phase I study	12
Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long‐acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double‐blind, p	12
Evaluation of potential drug–drug interactions with medical cannabis	12
Leveraging patient‐centric sampling for clinical drug development and decentralized clinical trials: Promise to reality	12
Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open‐label, multiple‐dose study	12
A drug‐disease model for predicting survival in an Ebola outbreak	12
Comparison of glutaminase and cancer antigen 125 for distinguishing benign and malignant ovarian tumors	12
Application of Machine Learning for Predicting Progression‐Free and Overall Survival in Patients With Renal Cell Carcinoma	12
An overview of drug‐induced sodium channel blockade and changes in cardiac conduction: Implications for drug safety	12
Application of a patient‐centered reverse translational systems‐based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors	12
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT‐787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial	12
Effect of carrot intake on glucose tolerance, microbiota, and gene expression in a type 2 diabetes mouse model	12
Optimizing expert and patient input in pediatric trial design: Lessons learned and recommendations from a collaboration between conect4children and European Patient‐CEntric ClinicAl TRial PLatforms	12
MicroRNA sequencing in patients with coronary artery disease – considerations for use as biomarker for thrombotic risk	12
Critical Roles for Modeling and Simulation and Real‐World Evidence to Inform Challenges in Clinical Trial Diversity Planning	12
Updated DPYDHapB3 haplotype structure and implications for pharmacogenomic testing	11
Association of Vancomycin Plus Piperacillin‐Tazobactam With Acute Kidney Injury: Differentiating Pseudo‐Injury From True Nephrotoxicity	11
Cardiac sodium channel inhibition by lamotrigine: In vitro characterization and clinical implications	11
Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy	11
No drug–drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants	11
	11
A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens	11
Key Stakeholders' Knowledge, Opinions, and Interests on Real‐World Evidence in the Regulatory Process—Results of an EU ‐Wide Survey	11
Feasibility of preemptive pharmacogenetic testing and improvement of medication treatment satisfaction among medically underserved patients	11
An exploratory machine learning approach to identify placebo responders in pharmacological binge eating disorder trials	11
Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC	11

Generic substitution of amlodipine is not associated with increased risk of mortality or adverse cardiovascular events: An observational cohort study	11
	11
Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A	11
Issue Information	11
Issue Information	11
Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations	11
Postmarket safety communications on drugs approved in Japan: A 25‐year analysis	11
Subtyping treatment response of tirofiban in acute ischemic stroke based on neuroimaging features	11
Informing Implementation Strategies for Pharmacogenomics in Cancer: Development of Survey Tools for Healthcare Professionals and Consumers	11
A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects	11
Allelic variation in HLA‐DRB1 is associated with development of a ntidrug	10
Association between serum albumin to serum creatinine ratio and mortality risk in patients with heart failure	10
How AI Transforms Regulatory Submission: Current Clinical Implementation and Future Prospects	10
Expression of Concern: Liu, X., Zhong, L., Li, P., & Zhao, P. MicroRNA‐100 Enhances Autophagy and Suppresses Migration and Invasion of Renal Cell Carcinoma Cells via Disruption of NOX4‐Depe	10
Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?	10
Drug Interaction PBPK Modeling: Review of the Literature Exposes the Need for Increased Verification of Model Inputs and Outputs as Part of Credibility Assessment	10
Potential biomarkers for fatal outcome prognosis in a cohort of hospitalized COVID ‐19 patients with pre‐existing comorbidities	10
Atogepant: Mechanism of action, clinical and translational science	10
Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose‐escalation phase I study	10
Use of Biomarkers in Drug Development for Regulatory Purposes	10
Regulation of exosomes as biologic medicines: Regulatory challenges faced in exosome development and manufacturing processes	10
	10
A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens	10
Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro	10
Clinical Pharmacology Approaches to Predict Efficacy of Monoclonal Antibodies Against Emerging SARS ‐ CoV	10
Remimazolam versus propofol in combination with esketamine for surgical abortion: A double‐blind randomized controlled trial	10
Considerations for addressing anti‐vaccination campaigns: How did we get here and what can we do about it?	10
Issue Information	10
High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID‐19 Treatment	10
Opportunities and challenges of 5G network technology toward precision medicine	10
Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole	10
A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence	9
Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review	9
Decentralized Clinical Trials in the Era of Real‐World Evidence: A Statistical Perspective	9
Controlled oxygenated rewarming as novel end‐ischemic therapy for cold stored liver grafts. A randomized controlled trial	9
Pharmacokinetics of Bocidelpar, ASP0367, in Renal and Hepatic Impairment: Results From Two Phase 1 Studies	9
AAV Gene Therapy Drug Development and Translation of Engineered Ocular and Neurotropic Capsids: A Systematic Review Using Natural Language Processing	9
Differential effects of metformin‐mediated BSEP repression on pravastatin and bile acid pharmacokinetics in humans: A randomized controlled trial	9
Large‐Scale Analysis of Age and Sex Effects on Corrected QT and JT Intervals: Insights From Hospital‐Based Controls and Moxifloxacin‐Treated Cases	9
Age‐related off‐label drug prescribing in pediatric patients in South Korea and consistency of labeling compared to the United States, Europe, and Japan	9
Re‐discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions	9
	9
First‐In‐Human, Randomized, Placebo‐Controlled, SAD and MAD Trial to Evaluate Safety, Tolerability, and PK/PD Modeling of Potravitug in Healthy Adults	9
Standardization, Education, and Resourcing: The Way Forward for Implementing Polygenic Risk Scores in Hereditary Breast and Ovarian Cancer	9
Proteomics Used in Identifying Novel Correlates of Disease in Pediatric Metabolic Dysfunction‐Associated Steatotic Liver Disease	9
Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors	9
Pharmacokinetics and Safety of Fixed‐Dose Versus Separate Enavogliflozin/Gemigliptin Combinations, and Food Effect on Enavogliflozin in Healthy Korean Subjects	9
Safety, Tolerability, and Pharmacokinetics of NIM‐1324 an Oral LANCL2 Agonist in a Randomized, Double‐Blind, Placebo‐Controlled Phase I Clinical Trial	9
Issue Information	9
Global harmonization of immediate‐release solid oral drug product bioequivalence recommendations and the impact on generic drug development	9
Surfing the T Wave: A Primer on ECG T Wave Morphologies Encountered in Clinical Trials and Impact on the QT Interval and Patient Safety	9
Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study	8
Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients	8
Pharmacogenomic variation and sedation outcomes during early intensive care unit admission: A pragmatic study	8
In Vitro Diagnostics for SARS ‐ CoV ‐2 Infection Authorized in the United States and Approved in J	8
Safety, Pharmacokinetics and Target Engagement of a Novel Brain Penetrant RIPK1 Inhibitor (SIR9900) in Healthy Adults and Elderly Participants	8
Thai pharmacogenomics database −2 (TPGxD‐2) sequel to TPGxD‐1, analyzing genetic variants in 26 non‐VIPGx genes within the Thai population	8
Association between psychomotor function and ALDH2 genotype after consuming barley shochu: A randomized crossover trial	8
A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS‐CoV‐2(−)/(+) populations	8
Predicting Vancomycin Clearance in Neonates and Infants by Integrating Machine Learning and Metabolomics With Population Pharmacokinetics	8
Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism	8
Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer	8
Rapid identification and phenotyping of nonalcoholic fatty liver disease patients using a machine‐based approach in diverse healthcare systems	8
The expanding universe of NUTM1 fusions in pediatric cancer	8
Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole	8
Translational researchers’ training and development needs, preferences, and barriers: A survey in a National Institute for Health Research Biomedical Research Centre in the United Kingdom	8
Leveraging large observational studies to discover genetic determinants of drug concentrations: A proof‐of‐concept study	8
Pharmacokinetic comparison of subcutaneously administered CT‐P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants	8
Pharmacokinetics and Safety of Polaprezinc Granules Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions	8
The Cardiac Sodium Channel Safety Profile of Cenobamate at Therapeutic Concentrations: In Vitro Analyses	8
Association of CYP2C19 genotypes with postoperative atrial fibrillation after coronary artery bypass surgery	8
Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data	8
Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer	8
Effect of enzalutamide on PK of P‐gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters	8
Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like re	8
Integrating Sustainability Pillars Into Trial Design Decision‐Making: Results of an International Survey	8
Tutorial: Microbiome studies in drug metabolism	8
Developing a mechanistic translational PK/PD model for a trifunctional NK cell engager to predict the first‐in‐human dose for acute myeloid leukemia	8
BLOODPAC: Collaborating to chart a path towards blood‐based screening for early cancer detection	8
Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double‐blind placebo‐controlled cross‐over study	8
Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti‐ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies	8
Optimizing a therapy for opiate use disorders: Characterizing ondansetron pharmacokinetics in blood and brain	8
Umbilical cord blood–derived exosomes from healthy term pregnancies protect against hyperoxia‐induced lung injury in mice	8
Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers	8
Factors influencing new‐onset hypertension in elderly patients with obstructive sleep apnea: A multicenter cohort study	7
Clinical Outcomes and Safety Profiles of Generic Versus Brand‐Name Clopidogrel in Patients Following Coronary Artery Stent Placement	7
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK‐001 using a randomized, double‐blind, placebo‐controlled study design	7
Integrating real‐world data to accelerate and guide drug development: A clinical pharmacology perspective	7
A multi‐purpose Japanese phase I study in the global development of vupanorsen: Randomized, placebo‐controlled, single‐ascending dose study in adults	7
Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study	7
Healthcare professionals' and consumers' knowledge, attitudes, perspectives, and education needs in oncology pharmacogenomics: A systematic review	7
Savor the flavor: A randomized double‐blind study assessing taste‐enhanced placebo analgesia in healthy volunteers	7
Association of Metabolic Genotype Composite CYP3A5*3 and CYP3A4*1B to Tacrolimus Pharmacokinetics in Stabl	7
Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data	7
Empowering drug development: Leveraging insights from imaging technologies to enable the advancement of digital health technologies	7